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PD-1 (Programmed Death-1) has been classified as a
marker of T-cell exhaustion, however, several recent stu-
dies suggest that most PD-1 high T-cells are highly pro-
liferative effector memory cells that maintain effector
function during chronic infection.Furthermore, activation
of PD-1 on T-cells is thought to inhibit antigen-specific
T-cell priming and regulate T-cell differentiation. Thus,
we sought to measure the drug-specific activation of
naïve T-cells after perturbation of PD-L1/2/PD-1 binding
and investigate whether PD-1 signalling influences the
differentiation of T-cells. Naive T-cells were cocultured
with monocyte-derived dendritic cells in the presence of
a drug (flucloxacillin, nitroso sulfamethoxazole) for a per-
iod of 8 days (±PD-L1/2 block), to expand the number of
drug-responsive T-cells. The T-cells were then incubated
with fresh dendritic cells and the drug. The antigen
responsiveness was analyzed using readouts for prolifera-
tion, cytokine secretion, and cell phenotype. Cell pheno-
type was characterised by flow cytometry. T-cell clones
were generated following priming and from drug hyper-
sensitive patients to characterize the cytokine signature
(s) of antigen specific T-cells and to study whether PD-1
expression/signalling governs the differentiation of
T-cells into effector/helper subsets. Priming of naïve
CD4+ and CD8+ T-cells against drug antigens was found
to be more effective when PD-L1 signaling was blocked.
Upon restimulation, T-cells proliferated more vigorously
and secreted increased levels of IFN-g, IL-13 and IL-22,
but not IL-17. Naïve T-cells expressed low levels of PD-
1; however, CFSE analysis revealed a transient increase
during priming. Drug-specific T-cell clones generated
through priming and from hypersensitive patients were
found to secrete IFN-g, IL-5 and IL-13. More detailed
analysis revealed two different cytokine signatures.
Clones secreted either FasL/IL-22 or granzyme B. The
FasL/IL-22 secreting clones expressed the skin homing
receptors CCR4, CCR10 and CLA and migrated in
response to CCL17/CCL27. PD-1 was stably expressed at
different levels on clones; however, PD-1 expression did
not correlate with the strength of the antigen-specific
proliferative response or the secretion of cytokines/cyto-
lytic molecules. This study shows that PD-L1/PD-1 bind-
ing negatively regulates the priming of drug-specific T-
cells. ELIspot analysis uncovered an antigen-specific
FasL/IL-22 secreting T-cell subset with skin homing
properties.
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